|
1
|
World Health Organization: GLOBOCAN 2012:
Estimated cancer incidence, Mortality and Prevalence Worldwide in
2012. v1.0.
|
|
2
|
National Cancer Registry Programme
(India): Three-Year Report of Population Based Cancer Registries
2012–2014.
|
|
3
|
Nagrani R, Budukh A, Koyande S, Panse NS,
Mhatre SS and Badwe R: Rural urban differences in breast cancer in
India. Indian J Cancer. 51:277–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Agarwal G and Ramakant P: Breast cancer
care in India: The current scenario and the challenges for the
future. Breast Care (Basel). 3:21–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lao J, Madani J, Puértolas T, Alvarez M,
Hernández A, Pazo-Cid R, Artal A and Torres Antón A: Liposomal
doxorubicin in the treatment of breast cancer patients: A review. J
Drug Deliv. 2013:4564092013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hortobagyi GN: Treatment of breast cancer.
N Engl J Med. 339:974–984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ellis MJ, Hayes DF and Lippman ME:
Treatment of metastatic breast cancerDisease of the breast. Harris
JR, Lippman ME, Morrow M, et al: Lippincott Williams & Wilkins;
4th ed. Philadelphia: pp. 7492000
|
|
8
|
Henderson IC: Chemotherapy for metastatic
diseaseBreast disease. Harris JR, Hellman S, Henderson IC, et al:
J.B. Lippincott Company; 2nd ed. Philadelphia: pp. 604–665.
1991
|
|
9
|
Sánchez-Moreno P, Boulaiz H,
Ortega-Vinuesa JL, Peula-García JM and Aránega A: Novel drug
delivery system based on docetaxel-loaded nanocapsules as a
therapeutic strategy against breast cancer cells. Int J Mol Sci.
13:4906–4919. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Norris LB, Qureshi ZP, Bookstaver PB,
Raisch DW, Sartor O, Chen H, Chen Fei and Bennett CL: Polysorbate
80 hypersensitivity reactions: A renewed call to action. Commun
Oncol. 7:425–428. 2010. View Article : Google Scholar
|
|
11
|
Fumoleau P, Chevallier B, Kerbrat P,
Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N,
Bougon N, Riva A and Roche H: A multicentre phase II study of the
efficacy and safety of docetaxel as first-line treatment of
advanced breast cancer: Report of the Clinical Screening Group of
the EORTC. Ann Oncol. 7:165–171. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
ten Tije AJ, Verweij J, Loos WJ and
Sparreboom A: Pharmacological effects of formulation vehicles:
Implications for cancer chemotherapy. Clin Pharmacokinet.
42:665–685. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gelderblom H, Verweij J, Nooter K and
Sparreboom A: Cremophor EL: The drawbacks and advantages of vehicle
selection for drug formulation. Eur J Cancer. 37:1590–1598. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Jonge ME, Huitema AD, Schellens JH,
Rodenhuis S and Beijnen JH: Population pharmacokinetics of orally
administered paclitaxel formulated in Cremophor EL. Br J Clin
Pharmacol. 59:325–334. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
O'Brien ME, Wigler N, Inbar M, Rosso R,
Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP,
et al: Reduced cardiotoxicity and comparable efficacy in a phase
III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil)
versus conventional doxorubicin for first-line treatment of
metastatic breast cancer. Ann Oncol. 15:440–449. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tzakos AG, Briasoulis E, Thalhammer T,
Jäger W and Apostolopoulos V: Novel oncology therapeutics: Targeted
drug delivery for cancer. J Drug Deliv. 2013:9183042013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kushwaha SK, Rastogl A, Rai A and Singh S:
Novel drug delivery system for anticancer drug: a review. Int J
PharmTech Res. 4:pp542–553. 2012.
|
|
18
|
Taxotere Prescribing Information:
Sanofi-aventis. U.S. LLC; NJ 08807: Revised. May. 2015
|
|
19
|
Harvey V, Mouridsen H, Semiglazov V,
Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M and Cold S:
Phase III trial comparing three doses of docetaxel for second-line
treatment of advanced breast cancer. J Clin Oncol. 24:4963–4970.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Comprehensive Cancer Network
(NCCN): Breast Cancer Guidelines. 2017.
|
|
21
|
Mavroudis D, Papakotoulas P, Ardavanis A,
Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos
A, Christophyllakis C, et al: Randomized phase III trial comparing
docetaxel plus epirubicin versus docetaxel plus capecitabine as
first-line treatment in women with advanced breast cancer. Ann
Oncol. 21:48–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marty M, Cognetti F, Maraninchi D, Snyder
R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A,
et al: Randomized phase II trial of the efficacy and safety of
trastuzumab combined with docetaxel in patients with human
epidermal growth factor receptor 2-positive metastatic breast
cancer administered as first-line treatment: The M77001 study
group. J Clin Oncol. 23:4265–4274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Esteva FJ, Valero V, Booser D, Guerra LT,
Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche
HA, et al: Phase II study of weekly docetaxel and trastuzumab for
patients with HER-2-overexpressing metastatic breast cancer. J Clin
Oncol. 20:1800–1808. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg
R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al:
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast
cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miles DW, Chan A, Dirix LY, Cortés J,
Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F,
et al: Phase III study of bevacizumab plus docetaxel compared with
placebo plus docetaxel for the first-line treatment of human
epidermal growth factor receptor 2-negative metastatic breast
cancer. J Clin Oncol. 28:3239–3247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Glück S, Russell C, O'Shaughnessy J,
McKenna EF, Hu S, Odom D and Blum JL: Treatment effect of
capecitabine and docetaxel or docetaxel alone by oestrogen receptor
status in patients with metastatic breast cancer: Results of an
exploratory analysis. Breast. 22:1087–1093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan Y, Xu BH, Yuan P, et al:
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in
the first-line treatment of metastatic triple-negative breast
cancer. Ann Oncol. 24:1219–1225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ashraf M, Sajjad R, Khan M, Shah M, Bhat Y
and Wani Z: 156P-Efficacy and safety of a novel nanosomal docetaxel
lipid suspension (NDLS) as an anti cancer agent-a retrospective
study. Ann Oncol. 27 Suppl 9:i×46–i×51. 2016. View Article : Google Scholar
|
|
29
|
Rivera E, Mejia JA, Arun BK, Adinin RB,
Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN
and Valero V: Phase 3 study comparing the use of docetaxel on an
every-3-week versus weekly schedule in the treatment of metastatic
breast cancer. Cancer. 112:1455–1461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nuzzo F, Morabito A, Gravina A, Di Rella
F, Landi G, Pacilio C, Labonia V, Rossi E, De Maio E, Piccirillo
MC, et al: Effects on quality of life of weekly docetaxel-based
chemotherapy in patients with locally advanced or metastatic breast
cancer: Results of a single-centre randomized phase 3 trial. BMC
Cancer. 11:752011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Seidman AD, Berry D, Cirrincione C, Harris
L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, et
al: Randomized phase III trial of weekly compared with
every-3-weeks paclitaxel for metastatic breast cancer, with
trastuzumab for all HER-2 overexpressors and random assignment to
trastuzumab or not in HER-2 nonoverexpressors: Final results of
Cancer and Leukemia Group B protocol 9840. J Clin Oncol.
26:1642–1649. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wist EA, Mjaaland I, Løkkevik E and Sommer
H: Weekly paclitaxel plus capecitabine versus docetaxel every 3
weeks plus capecitabine in metastatic breast cancer. J Oncol.
2012:8629212012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang L and Zhang N: How nanotechnology
can enhance docetaxel therapy. Int J Nanomedicine. 8:2927–2941.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ahmad A, Sheikh S, Ali SM, Ahmad MU,
Paithankar M, Saptarishi D, Maheshwari K, Kumar K, Singh J, Patel
GN, et al: Development of aqueous based formulation of docetaxel:
Safety and pharmacokinetics in patients with advanced solid tumors.
J Nanomed Nanotechnol. 6:2952015.
|
|
35
|
Ahmad A, Sheikh S, Taran R, Srivastav SP,
Prasad K, Rajappa SJ, Kumar V, Gopichand M, Paithankar M, Sharma M,
et al: Therapeutic efficacy of a novel nanosomal docetaxel lipid
suspension compared with taxotere in locally advanced or metastatic
breast cancer patients. Clin Breast Cancer. 14:177–181. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Seidman AD, Tiersten A, Hudis C, Gollub M,
Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, et al:
Phase II trial of paclitaxel by 3-hour infusion as initial and
salvage chemotherapy for metastatic breast cancer. J Clin Oncol.
13:2575–2581. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Taxol Prescribing Information.
Bristol-Myers Squibb Company; Princeton, NJ 08543: Revised. April.
2011
|
|
38
|
Perez EA, Vogel CL, Irwin DH, Kirshner JJ
and Patel R: Multicenter phase II trial of weekly paclitaxel in
women with metastatic breast cancer. J Clin Oncol. 19:4216–4223.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Datko F, D'Andrea G, Dickler M, Theodoulou
M, Goldfarb S, Lake D, Fornier M, Modi S, Sklarin N, Comen E, et
al: Abstract P5-18-20: Phase II study of pertuzumab, trastuzumab,
and weekly paclitaxel in patients with metastatic
HER2-overexpressing metastatic breast cancer. Cancer Res. 72 24
Suppl:Abstract nr P5. 18–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Delaloge S, Pérol D, Courtinard C, Brain
E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C,
et al: Paclitaxel plus bevacizumab or paclitaxel as first-line
treatment for HER2-negative metastatic breast cancer in a
multicenter national observational study. Ann Oncol. 27:1725–1732.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J,
Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, et al: Cisplatin plus
gemcitabine versus paclitaxel plus gemcitabine as first-line
therapy for metastatic triple-negative breast cancer (CBCSG006): A
randomised, open-label, multicentre, phase 3 trial. Lancet Oncol.
16:436–446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Saloustros E, Nikolaou M, Kalbakis K,
Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N,
Kourousis C, Vamvakas L, Georgoulias V and Mavroudis D: Weekly
paclitaxel and carboplatin plus bevacizumab as first-line treatment
of metastatic triple-negative breast cancer. A Multicenter Phase II
Trial by the Hellenic Oncology Research Group. Clin Breast Cancer.
18:88–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mauri D, Kamposioras K, Tsali L,
Bristianou M, Valachis A, Karathanasi I, Georgiou C and Polyzos NP:
Overall survival benefit for weekly vs. three-weekly taxanes
regimens in advanced breast cancer: A meta-analysis. Cancer Treat
Rev. 36:69–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Trissel LA: Pharmaceutical properties of
paclitaxel and their effects on preparation and administration.
Pharmacotherapy. 17:133S–139S. 1997.PubMed/NCBI
|
|
46
|
Abraxane Prescribing Information. Abraxis
BioScience, LLC. Revised. September. 2013
|
|
47
|
Gradishar WJ, Tjulandin S, Davidson N,
Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III
trial of nanoparticle albumin-bound paclitaxel compared with
polyethylated castor oil-based paclitaxel in women with breast
cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gradishar WJ, Krasnojon D, Cheporov S,
Makhson AN, Manikhas GM, Clawson A and Bhar P: Significantly longer
progression-free survival with nab-paclitaxel compared with
docetaxel as first-line therapy for metastatic breast cancer. J
Clin Oncol. 27:3611–3619. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Blum JL, Savin MA, Edelman G, Pippen JE,
Robert NJ, Geister BV, Kirby RL, Clawson A and O'Shaughnessy JA:
Phase II study of weekly albumin-bound paclitaxel for patients with
metastatic breast cancer heavily pretreated with taxanes. Clin
Breast Cancer. 7:850–856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Danso MA, Blum JL, Robert NJ, Krekow L,
Rotche R, Smith DA, Richards P, Anderson T, Richards DA and
O'Shaughnessy J: Phase II trial of weekly nab-paclitaxel in
combination with bevacizumab as first-line treatment in metastatic
breast cancer. J Clin Oncol. 26 15 Suppl:S10752008. View Article : Google Scholar
|
|
51
|
Conlin AK, Seidman AD, Bach A, Lake D,
Dickler M, D'Andrea G, Traina T, Danso M, Brufsky AM, Saleh M, et
al: Phase II trial of weekly nanoparticle albumin-bound paclitaxel
with carboplatin and trastuzumab as first-line therapy for women
with HER2-overexpressing metastatic breast cancer. Clin Breast
Cancer. 10:281–287. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mirtsching B, Cosgriff T, Harker G, Keaton
M, Chidiac T and Min M: A phase II study of weekly nanoparticle
albumin-bound paclitaxel with or without trastuzumab in metastatic
breast cancer. Clin Breast Cancer. 11:121–128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hamilton E, Kimmick G, Hopkins J, Marcom
PK, Rocha G, Welch R, Broadwater G and Blackwell K:
Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line
triple negative metastatic breast cancer. Clin Breast Cancer.
13:416–420. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jain MM, Gupte SU, Patil SGP, et al:
Paclitaxel injection concentrate for nanodispersion versus
nab-paclitaxel in women with metastatic breast cancer: A
multicenter, randomized, comparative phase II/III study. Breast
Cancer Res Treat. 156:125–134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ranade AA, Bapsy PP, Nag S, Raghunadharao
D, Raina V, Advani SH, Patil S, Maru A, Gangadharan VP, Goswami C,
et al: A multicenter phase II randomized study of Cremophor-free
polymeric nanoparticle formulation of paclitaxel in women with
locally advanced and/or metastatic breast cancer after failure of
anthracycline. Asia Pac J Clin Oncol. 9:176–181. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ahmad A, Sheikh S, Ali SM, Paithankar M,
Mehta A, Nagarkar R, Krishnan S, Majumdar A, Mukherjee KK, Singh
JK, et al: Nanosomal paclitaxel lipid suspension demonstrates
higher response rates compared to paclitaxel in patients with
metastatic breast cancer. J Cancer Sci Ther. 7:116–120. 2015.
|
|
57
|
Doxorubicin Prescribing Informaiton.
Pharmacia & Upjohn Company; Kalamazoo, MI 49001: Revised. May.
2003
|
|
58
|
Rafiyath SM, Rasul M, Lee B, Wei G, Lamba
G and Liu D: Comparison of safety and toxicity of liposomal
doxorubicin vs. conventional anthracyclines: A meta-analysis. Exp
Hematol Oncol. 1:102012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xing M, Yan F, Yu S and Shen P: Efficacy
and cardiotoxicity of liposomal doxorubicin-based chemotherapy in
advanced breast cancer: a meta-analysis of ten randomized
controlled trials. PloS one. 10:e01335692015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cowens JW, Creaven PJ, Greco WR, Brenner
DE, Tung Y, Ostro M, Pilkiewicz F, Ginsberg R and Petrelli N:
Initial clinical (phase I) trial of TLC D-99 (doxorubicin
encapsulated in liposomes). Cancer Res. 53:2796–2802.
1993.PubMed/NCBI
|
|
61
|
Hong RL, Huang CJ, Tseng YL, Pang VF, Chen
ST, Liu JJ and Chang FH: Direct comparison of liposomal doxorubicin
with or without polyethylene glycol coating in C-26 tumor-bearing
mice: Is surface coating with polyethylene glycol beneficial? Clin
Cancer Res. 5:3645–3652. 1999.PubMed/NCBI
|
|
62
|
Gabizon A and Martin F: Polyethylene
glycol-coated (pegylated) liposomal doxorubicin. Rationale for use
in solid tumours. Drugs. 54 Suppl 4:S15–S21. 1997. View Article : Google Scholar
|
|
63
|
Gabizon AA: Pegylated liposomal
doxorubicin: Metamorphosis of an old drug into a new form of
chemotherapy. Cancer Invest. 19:424–436. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Simůnek T, Stérba M, Popelová O, Adamcová
M, Hrdina R and Gersl V: Anthracycline-induced cardiotoxicity:
overview of studies examining the roles of oxidative stress and
free cellular iron. Pharmacol Rep. 61:154–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Caelyx® summary of product
characteristics. Janssen-Cilag International NV; Beerse, Belgium:
Revised. January. 2017
|
|
66
|
Gordon AN, Fleagle JT, Guthrie D, Parkin
DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma:
A randomized phase III study of pegylated liposomal doxorubicin
versus topotecan. J Clin Oncol. 19:3312–3322. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Al-Batran SE, Güntner M, Pauligk C, et al:
Anthracycline rechallenge using pegylated liposomal doxorubicin in
patients with metastatic breast cancer: A pooled analysis using
individual data from four prospective trials. Br J Cancer.
103:1518–1523. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Smorenburg CH, De Groot SM, van
Leeuwen-Stok AE, et al: A randomized phase III study comparing
pegylated liposomal doxorubicin with capecitabine as first-line
chemotherapy in elderly patients with metastatic breast cancer:
Results of the OMEGA study of the Dutch Breast Cancer Research
Group BOOG. Ann Oncol. 25:599–605. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chia S, Clemons M, Martin LA, Rodgers A,
Gelmon K, Pond GR and Panasci L: Pegylated liposomal doxorubicin
and trastuzumab in HER-2 overexpressing metastatic breast cancer: A
multicenter phase II trial. J Clin Oncol. 24:2773–2778. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Martín M, Sánchez-Rovira P, Muñoz M, et
al: Pegylated liposomal doxorubicin in combination with
cyclophosphamide and trastuzumab in HER2-positive metastatic breast
cancer patients: Efficacy and cardiac safety from the
GEICAM/2004-05 study. Ann Oncol. 22:2591–2596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ali SM, Sheikh S, Ahmad A, Ahmad MU, et
al: Bioequivalence study of pegylated doxorubicin hydrochloride
liposome (PEGADRIA) and DOXIL® in ovarian cancer
patients: Physicochemical characterization and pre-clinical
studies. J Nanomed Nanotechnol. 7:3612016.
|
